How to improve loco-regional control in stages IIIa-b NSCLC?. Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group

Lung Cancer

Volumn 65, Issue 1, 2009, Pages 62-67

  Nyman, J ^a   Friesland, S ^b   Hallqvist, A ^a   Seke, M ^c   Bergstrom S ^d   Thaning, L ^e   Loden B ^f   Sederholm, C ^g   Wagenius, G ^h  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d GÄVLE HOSPITAL   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f CENTRAL HOSPITAL   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Accelerated radiotherapy; Carboplatin; Concurrent chemoradiation; Induction chemotherapy; Locally advanced; Non small cell lung cancer; Paclitaxel; Randomized trial

Indexed keywords

BETAMETHASONE; CARBOPLATIN; CIMETIDINE; CLEMASTINE; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ESOPHAGITIS; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SWEDEN; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 67349140361     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.10.021     Document Type: Article

References (31)

1. Nyman J., and Mercke C. Accelerated radiotherapy with docetaxel and cisplatin as induction and concomitant chemotherapy for stage III non-small cell lung cancer. Lung Cancer 29 Suppl. 1 (2000) 323, 98-9
2. Nyman J., Bergman B., and Mercke C. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small cell lung cancer-impact of total treatment time. Acta Oncol 37 (1998) 539-545
3. Brodin O., Wagenius G., and Helsing M. Daily paclitaxel and radiotherapy in patients with locally advanced non-small cell lung cancer. A phase I study. Proc Am Soc Clin Oncol 19 (2000) 516 [abstract 2022]
4. Sirzén F., Lamberg K., Mrazek E., Brandén E., Lönn U., and Sederholm C. Phase II study of weekly paclitaxel and carboplatin with concurrent thoracic radiation therapy for locally advanced NSCLC. Proc Am Soc Clin Oncol 20 (2001) 254b [abstract 2768]
5. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
6. Jassem J. Combined chemotherapy and radiation in locally advanced non small-cell lung cancer. Lancet Oncol 2 (2001) 335-342
7. Vokes E.E., Herndon J.E., Kelly M.J., Cicchetti M.G., Ramnath N., Neill H., et al. Induktion chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small cell lung cancer: Cancer and Leukaemia Group B. J Clin Oncol 25 (2007) 1698-1704
8. Gouda Y.S., Kohali H.M., Eldeeb N.A., Omar A.M., El-Geneidy M.M., and Elkerm Y.M. Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with or without prior induction chemotherapy in patients with locally advanced non-small cell lung cancer. J Egypt Natl Canc Inst 18 (2006) 73-81
9. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination wiyh mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
10. Curran W., Scott C., Langer C., Komaki R., Lee J., Hauser S., et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 29 Suppl. 1 (2000) 303, 93
11. Saunders M., Dische S., Barret A., Harvey A., Gibson D., and Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet 350 (1997) 161-165
12. Belani C.P., Wang W., Johnsson D.H., Wagner H., Shiller J., Veeder M., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
13. Ball D., Bishop J., Smith J., O'Brien P., Davis S., Ryan G., et al. A randomised Phase III study of standard fractionation radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 52 (1999) 129-136
14. Nasroulah F., O'connor J.M., Van Kooten M., Tajer C., and Chacon R.D. Hyperfractionated (HFRT) versus standard radiotherapy (SRT) in locally advanced (LA) NSCLC: a metaanalysis of randomized phase III trials. J Thorac Oncol 2 Suppl. 4 (2007) 477
15. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 23 (2005) 5883-5891
16. Oral E.N., Aydiner A., Erlap Y., and Topuz E. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer. Med Oncol 22 (2005) 367-374
17. Giorgio C.G., Pappalardo A., Russo A., Santini D., Di Rosa C., Di Salvo C., et al. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Anticancer Drugs 18 (2007) 713-719
18. Pallarés C., Capdevila J., Paredes A., Farré N., Ciria J.P., Membrive I., et al. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Lung Cancer 58 (2007) 238-245
19. Huber R.M., Flentje M., Schmidt M., Pöllinger B., Gosse H., Willner J., et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/)/by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24 (2006) 4397-4404
20. Gobitti C., Franchin G., Minatel E., Gigante M., Basso B., Bujor L., et al. Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: a phase I study. Oncol Rep 14 (2005) 1647-1653
21. Rathmann J., Leopolgd K.A., and Rigas J.R. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin Radiat Oncol 9 (1999) 130-135
22. Rosenthal D.I., Fuller C.D., Machtay M., Algazy K.M., Meyer D.M., Kaiser L.R., et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer. J Thorac Oncol 1 (2006) 38-45
23. Jeremic B., Milicic B., Acimovic L., and Milisavljevic S. Concurrant hyperfractionated radiotherapy and low-dose daily carboplatin7paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol 23 (2005) 6873-6880
24. Chen Y., Pandya K., Keng P.C., Johnstone D., Li J., Lee Y.J., et al. Phase I/II clinical study of pulsed paclitaxel radiosensitazion for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cell lines. Clin Cancer Res 9 (2003) 969-975
25. Zanelli G.D., Quaia M., Robieux I., Bujor L., Santarosa M., Favaro D., et al. Paclitaxel as a radiosensitisier: proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33 (1997) 486-492
26. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
27. Russell A.H., Pajak T.E., Selim H.M., Paradelo J.C., Murray K., Bansal P., et al. Profylactic cranial irradiation for lung cancer patients at high risk for development for of cerebral metastasis: results of a prospective randomised trial conducted by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 21 (1991) 637-643
28. Miller T.P., Crowley J.J., Mira J., Schwartz J.G., Hutchins L., Baker L., et al. Randomized trial of chemotherapy and radiotherapy for stage III non-small cell lung cancer. Cancer Ther 4 (1998) 229-236
29. Umsawasdi T., Valdivieso M., Barkley H.T., Chen T., Booser D., Chinten D.F., et al. Combined chemotherapy in limited-disease inoperable non-small cell lung cancer. Int J Radiat Biol Phys 14 (1987) 43-48
30. Cox J.D., Stanley K., Petrovich Z., Paig C., and Yesner R. Cranial irradiation in cancer of the lung of all cell types. J Am Med Assoc 245 (1981) 469-472
31. Lester J.F., Coles B., and Macbeth F.R. Profylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. Cochrane Database Syst Rev 2 (2005) 5221